Skip to content

Current ratio at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.6×
Arrowhead Research logo
Arrowhead ResearchARWR
6.2×+1.1×
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
22.6×+1.6×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Scholar Rock logo
Scholar RockSRRK
8.6×-1.6×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
7.1×+1.0×

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.27B+153%
Enterprise value$2.69B+228%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s current ratio?
Dyne Therapeutics, Inc. (DYN) reported current ratio of 19.9× in Q1 2026.
How has Dyne Therapeutics, Inc.'s current ratio changed year-over-year?
Dyne Therapeutics, Inc.'s current ratio decreased by 2.1% year-over-year, from 20.4× to 19.9×.
What is the long-term trend for Dyne Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s current ratio has grown at a -6.9% compound annual growth rate (CAGR), from 31.8× to 22.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.